SREBP-1c is positively regulated by hyperactivaiton of mechanistic target of rapamycin complex 1 (mTORC1) manifested in NAFLD, which promotes lipid synthesis (7–9). Here, SREBF1 is linked to metabolic dysfunction-associated steatotic liver disease.